<TABLE> <S> <C>


<ARTICLE>         5
<LEGEND>
                  This schedule contains summary financial information extracted
                  from Rocky  Point  Pharmaceuticals,  Inc.  September  30, 2000
                  financial  statements  and is  qualified  in its  entirety  by
                  reference to such financial statements.
</LEGEND>

<CIK>                    0000853465
<NAME>                   Rocky Point Pharmaceuticals, Inc.
<CURRENCY>               US



<S>                           <C>
<PERIOD-TYPE>                 9-MOS
<FISCAL-YEAR-END>             DEC-31-2000
<PERIOD-END>                  SEP-30-2000
<EXCHANGE-RATE>               1.00

<CASH>                             0
<SECURITIES>                       0
<RECEIVABLES>                      0
<ALLOWANCES>                       0
<INVENTORY>                        0
<CURRENT-ASSETS>                   0
<PP&E>                             0
<DEPRECIATION>                     0
<TOTAL-ASSETS>                     0
<CURRENT-LIABILITIES>              350
<BONDS>                            0
              0
                        0
<COMMON>                           1,000
<OTHER-SE>                         (1,350)
<TOTAL-LIABILITY-AND-EQUITY>       0
<SALES>                            0
<TOTAL-REVENUES>                   0
<CGS>                              0
<TOTAL-COSTS>                      0
<OTHER-EXPENSES>                   350
<LOSS-PROVISION>                   0
<INTEREST-EXPENSE>                 0
<INCOME-PRETAX>                    (350)
<INCOME-TAX>                       0
<INCOME-CONTINUING>                (350)
<DISCONTINUED>                     0
<EXTRAORDINARY>                    0
<CHANGES>                          0
<NET-INCOME>                       (350)
<EPS-BASIC>                        (.00)
<EPS-DILUTED>                      (.00)



</TABLE>



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission